Related Experiment Video

Updated: Oct 5, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K

Hesperidin: A Potential Therapeutic Agent against COVID-19

Ashwani K Dhingra1, Bhawna Chopra1, Vaibhav Rathi2

  • 1Guru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.

Current Drug Discovery Technologies
|October 20, 2022
PubMed

Insights

Hesperidin, a natural compound, shows promise as a potential treatment for COVID-19 (Coronavirus Disease 2019). This study explores its therapeutic benefits and multifaceted bioactivities for developing new anti-COVID-19 interventions.

Area of Science:

  • Pharmacology
  • Virology
  • Natural Products Chemistry

Background:

  • The global health crisis caused by Coronavirus Disease 2019 (COVID-19), a pandemic driven by SARS-CoV-2, necessitates urgent development of effective treatments.
  • The lack of specific antiviral therapies for COVID-19 highlights the need for novel therapeutic strategies.
  • Medicinal chemists are exploring natural compounds with established safety profiles for potential anti-COVID-19 applications.

Purpose of the Study:

  • To investigate the therapeutic potential of hesperidin, a flavonoid, in the prevention and management of COVID-19.
  • To review existing preclinical and clinical evidence supporting hesperidin's antiviral and immunomodulatory activities relevant to SARS-CoV-2 infection.
  • To propose hesperidin as a lead compound for developing novel anti-COVID-19 therapeutics.

Main Methods:

  • Literature review of preclinical studies on hesperidin's antiviral properties.
  • Analysis of recent clinical trial data investigating hesperidin's efficacy against COVID-19.
  • Examination of hesperidin's known bioactivities, including anti-inflammatory and antioxidant effects.

Main Results:

  • Hesperidin exhibits documented antiviral activity against various viruses.
  • Emerging studies suggest hesperidin may mitigate COVID-19 severity through its multifaceted bioactivities.
  • The compound demonstrates a favorable safety profile, making it a viable candidate for therapeutic development.

Conclusions:

  • Hesperidin presents a promising natural product for developing novel prophylactic and therapeutic interventions against COVID-19.
  • Further preclinical and clinical research is warranted to fully elucidate hesperidin's role in combating SARS-CoV-2.
  • Hesperidin's unique properties position it as a potential lead for future anti-COVID-19 drug discovery efforts.

Keywords:
COVID-19SARS-COV-2anti-inflammatory activityantiviral activityhesperidinimmunomodulatory

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

832
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

656

Related Concept Videos

Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...